Cash-strapped states are exploring a controversial new way to cut Medicaid expenses: limiting which drugs their beneficiaries can access.
The British Medical Journal ignited debate earlier this month when it announced that about half of cancer drugs approved by the European Medicines Agency don’t improve survival or quality of life. The claim begs several complex question: How can regulators evaluate drugs both quickly and effectively?
The Centers for Medicare and Medicaid Services’ Oncology Care Model is off and running. As announced during The White House’s cancer summit at Howard University, more than 200 physician practices and 3,200 oncologists have enrolled – effective July 1.
The Centers for Medicare and Medicaid Services’ newly proposed rule may reinvent how medications are paid for under Part B, which covers infused or injected medications administered in a clinic or hospital setting.